title: Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells.
abstract: Endoglin (CD105, END) is upregulated in proliferating endothelial cells, suggesting potential therapeutic properties. However, it is not clear whether endoglin mediates an enhanced proliferative rate or may be upregulated as part of a negative feedback loop. To gain insights into context-dependent and cell type-dependent regulatory effects of endoglin, we studied its role properties in human ovarian carcinoma-derived endothelial cells (ODMECs). We isolated and cultured primary ODMECs from epithelial ovarian carcinoma tissue. ODMECs had higher expression of endoglin and VEGFR-2, and also exhibited enhanced spontaneous formation of vessel-like structures in vitro. Transfection of siRNA targeting endoglin in ODMECs cells resulted in the reduction of the proliferation and tube formation. These results indicate that a subset of ODMECs display abnormal angiogenic properties and this phenotype was blocked by decreasing endoglin levels, suggesting endoglin is essential for stimulating angiogenesis, and targeting it may be an attractive approach to anti-angiogenesis therapy for ovarian carcinoma.
authors.affiliation: Department of Obstetrics and Gynecology; Southwest Hospital; Third Military Medical University; Chongqing, P.R. China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.forename: Dan
authors.initials: D
authors.lastname: Wang
authors.forename: Li-Mei
authors.initials: LM
authors.lastname: Zhao
authors.forename: Xi-Long
authors.initials: XL
authors.lastname: Zhao
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Shen
authors.forename: Yao
authors.initials: Y
authors.lastname: Xie
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Cao
authors.forename: Zhen-Bo
authors.initials: ZB
authors.lastname: Chen
authors.forename: Yan-Mei
authors.initials: YM
authors.lastname: Luo
authors.forename: Bi-Hui
authors.initials: BH
authors.lastname: Bao
authors.forename: Zhi-Qing
authors.initials: ZQ
authors.lastname: Liang
mesh_terms: D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism*; D002465:Cell Movement; D049109:Cell Proliferation; D048430:Cell Shape; D000071063:Endoglin; D042783:Endothelial Cells / Q000378:metabolism* / Q000502:physiology; D005260:Female; D055785:Gene Knockdown Techniques; D006801:Humans; D055806:Microvessels / Q000473:pathology; D009375:Neoplasms, Glandular and Epithelial / Q000098:blood supply / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000473:pathology*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D061251:Primary Cell Culture; D034741:RNA, Small Interfering / Q000235:genetics; D011956:Receptors, Cell Surface / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D034741:RNA, Small Interfering; D011956:Receptors, Cell Surface; D014841:von Willebrand Factor; D040301:Vascular Endothelial Growth Factor Receptor-2
keywords: ODMEC; endoglin; endothelial cells; ovarian carcinoma; siRNA
references.citation: Drug Resist Updat. 2008 Dec;11(6):219-30
references.pmid: 18948057
references.citation: Int J Exp Pathol. 2009 Jun;90(3):195-221
references.pmid: 19563606
references.citation: J Biol Chem. 2008 Nov 21;283(47):32527-33
references.pmid: 18775991
references.citation: Cell Tissue Res. 2009 Jan;335(1):205-22
references.pmid: 18677515
references.citation: Oncologist. 2009 Jul;14(7):706-16
references.pmid: 19592450
references.citation: FASEB J. 2003 Jun;17(9):1159-61
references.pmid: 12709414
references.citation: Cancer Res. 2004 Jul 1;64(13):4601-10
references.pmid: 15231672
references.citation: Mol Aspects Med. 2011 Apr;32(2):71-87
references.pmid: 21540050
references.citation: Diabetologia. 2013 Jan;56(1):222-4
references.pmid: 23104640
references.citation: J Cell Sci. 2007 Mar 15;120(Pt 6):964-72
references.pmid: 17311849
references.citation: J Clin Oncol. 2011 Feb 20;29(6):747-54
references.pmid: 21079135
references.citation: Cancer Sci. 2008 Mar;99(3):459-66
references.pmid: 18167133
references.citation: Tumour Biol. 2011 Jun;32(3):589-96
references.pmid: 21350924
references.citation: Lancet Oncol. 2013 Mar;14(3):236-43
references.pmid: 23333117
references.citation: J Biol Chem. 2005 Jul 29;280(30):27800-8
references.pmid: 15923183
references.citation: Cancer Res. 2004 Nov 15;64(22):8249-55
references.pmid: 15548691
references.citation: Int J Cancer. 2009 Sep 15;125(6):1446-53
references.pmid: 19533687
references.citation: Am J Obstet Gynecol. 2008 Nov;199(5):533.e1-8
references.pmid: 18533117
references.citation: Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1789-93
references.pmid: 17009973
references.citation: Genes Cancer. 2010 Jan;1(1):12-25
references.pmid: 21779425
references.citation: Biochim Biophys Acta. 2009 Oct;1792(10):954-73
references.pmid: 19607914
references.citation: Cancer Res. 2007 Feb 15;67(4):1757-68
references.pmid: 17308118
references.citation: Oncologist. 2012;17(8):1039-50
references.pmid: 22773560
references.citation: J Am Coll Surg. 2007 Mar;204(3):399-408
references.pmid: 17324773
references.citation: Microvasc Res. 2007 Sep-Nov;74(2-3):172-83
references.pmid: 17631914
references.citation: Nature. 2010 Dec 9;468(7325):829-33
references.pmid: 21102433
references.citation: Carcinogenesis. 2010 Mar;31(3):435-41
references.pmid: 20042635
references.citation: Clin Cancer Res. 2009 Apr 15;15(8):2695-702
references.pmid: 19351748
references.citation: Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11305-10
references.pmid: 18685096
references.citation: N Engl J Med. 2011 Dec 29;365(26):2484-96
references.pmid: 22204725
references.citation: Clin Cancer Res. 2013 Jan 1;19(1):170-82
references.pmid: 23147994
references.citation: Cancer Biol Ther. 2006 Nov;5(11):1539-45
references.pmid: 17102591
references.citation: Clin Cancer Res. 2011 Aug 15;17(16):5217-9
references.pmid: 21828238
references.citation: Anat Embryol (Berl). 1996 Nov;194(5):445-56
references.pmid: 8905012
references.citation: Int J Cancer. 2004 Jan 10;108(2):251-7
references.pmid: 14639611
references.citation: J Cell Biochem. 2007 Dec 15;102(6):1375-88
references.pmid: 17975795
references.citation: Cell Signal. 2010 Aug;22(8):1163-74
references.pmid: 20153821
references.citation: Blood. 2006 Apr 15;107(8):3027-33
references.pmid: 16373660
references.citation: Stem Cell Res. 2012 Jan;8(1):85-96
references.pmid: 22099023
references.citation: Clin Cancer Res. 2003 Sep 15;9(11):4221-6
references.pmid: 14519649
references.citation: Cancer Res. 2008 Oct 15;68(20):8626-34
references.pmid: 18922939
references.citation: Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28
references.pmid: 20061178
references.citation: Lab Invest. 2007 Nov;87(11):1159-70
references.pmid: 17876298
references.citation: Trends Mol Med. 2005 Mar;11(3):104-13
references.pmid: 15760768
references.citation: Mol Biol Cell. 2012 Jul;23(13):2412-23
references.pmid: 22593212
references.citation: J Clin Oncol. 2008 Feb 20;26(6):995-1005
references.pmid: 18195328
references.citation: FASEB J. 2000 Jan;14(1):55-64
references.pmid: 10627280
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4820-9
references.pmid: 22767667
references.citation: Cancer Lett. 2012 Aug 1;321(1):13-7
references.pmid: 22388173
references.citation: Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3056-61
references.pmid: 17591873
references.citation: Mol Ther. 2009 Aug;17(8):1316-32
references.pmid: 19491821
references.citation: Cardiovasc Res. 2010 Apr 1;86(1):12-9
references.pmid: 19812043
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: EMBO J. 2004 Oct 13;23(20):4018-28
references.pmid: 15385967